NCT05989620Recruiting
Long-Term Development of Muscular Dystrophy Outcome Assessments
Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005)
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 2 Aug 2023
- Start date
- 18 Oct 2023
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Virginia Commonwealth University
- Diseases
- Pompe disease
- NCT number
- NCT05989620
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 18 Oct 2023 to the primary completion date, 1 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in a clinical trial receiving an investigational product
Other illness
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator
Who the study is looking for
- Age between 6-50 years at enrollment
- Clinically affected (defined as weakness on bedside evaluation in a pattern consistent with proximal weakness)
- Genetic confirmation of a LGMD, DM2, or LOPD
- FVC above 30% of predicted
Age in the registry: 6 years to 50 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Virginia Commonwealth University Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.